Abstract
Modelling and simulation studies have been used to inform the choices and development of quality improvement (QI) initiatives in health care, for example, by helping refine the intervention to be implemented or support decisions around the management of demand and capacity. We do not know whether a modelling study can itself be informed by a QI project and what are the associated benefits and challenges. In this research, we sought to investigate the opportunities and challenges associated with an ongoing health service-led QI project in informing the development of a stochastic simulation-based decision support tool to inform decisions around the commissioning of anticoagulation services for patients with atrial fibrillation. We found that the positive synergies offered by the QI project included good access to stakeholders and envisaged end users, co-producing relevant and impactful scenarios for experimentation, as well as access to good quality individual patient level data. On the other hand, substantial effort was required to populate input parameters with values that pertain to the natural history of the disease and the effectiveness of the different treatments. Our findings indicate that, if stakeholders require modelling results to inform aspects of a QI project, upfront investment is needed to ensure timely interaction between the two studies.
| Original language | English |
|---|---|
| Journal | Health Systems |
| Early online date | 5 May 2025 |
| DOIs | |
| Publication status | E-pub ahead of print - 5 May 2025 |
Data Availability Statement
Parts of the data, such as those retrieved from the literature that support the findings of this study are available from the corresponding author, CV, upon reasonable request.Acknowledgements
Our thanks to Anna Burhouse and the clinicians, managers and healthcare professionals who contributed to the conduct of this study.Funding
JV is primarily supported by the Research Council of Norway HARMONI project [349559] and the Measure for Improved Availability of medicines and vaccines [300867]; and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [443158418]. Funding for this project was provided in part by Health Innovation West of England (at the time of the study called the West of England Academic Health Science Network).